Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Activation

Canadian Cancer Trials Group IND.198 -- A Phase I/II Study of Foretinib in Combination with Lapatinib in Patients with Human Epidermal Growth Factor Receptor 2(HER2) Positive Over-expressing Metastatic Breast Cancer - was centrally activated 3 June 2010.

http://www.ctg.queensu.ca/trials/ind/i198/198.html